Assignee
TOSK INC
US·18 granted patents·9 pending applications·74 citations·filing 1999–2025
Top patents by PatentIndex Score
27 records- 0192USRE48253EMethotrexate adjuvants to reduce toxicity and methods for using the sameTOSK INC·Filed 2018·Granted Oct 13, 2020·5 cites·29 claims
- 0290US7998967B2Methotrexate adjuvants to reduce toxicity and methods for using the sameTOSK INC·Filed 2009·Granted Aug 16, 2011·15 cites·13 claims
- 0389US11446303B2Uridine phosphorylase (UPase) inhibitors for treatment of liver conditionsTOSK INC·Filed 2020·Granted Sep 20, 2022·3 cites·18 claims
- 0484US11945803B2Modulators of RAS GTPaseTOSK INC·Filed 2019·Granted Apr 2, 2024·3 cites·9 claims
- 0583US9382287B2Methotrexate adjuvants to reduce toxicity and methods for using the sameTOSK INC·Filed 2014·Granted Jul 5, 2016·5 cites·16 claims
- 0677US12486255B2Modulators of RAS GTPaseTOSK INC·Filed 2024·Granted Dec 2, 2025·0 cites·17 claims
- 0774US2025049834A1Methods and Compositions for Treating MucositisTOSK INC·Filed 2024·Application pending·0 cites
- 0872US6855504B2In vivo high throughput toxicology screening methodTOSK INC·Filed 2001·Granted Feb 15, 2005·10 cites·16 claims
- 0968US12194043B2Uridine phosphorylase inhibitors to treat or prevent pulmonary diseaseTOSK INC·Filed 2021·Granted Jan 14, 2025·0 cites·20 claims
- 1067US12109222B2Methods and compositions for treating mucositisTOSK INC·Filed 2021·Granted Oct 8, 2024·0 cites·20 claims
- 1163US2024091228A1Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary DysfunctionTOSK INC·Filed 2023·Application pending·0 cites
- 1263US2023255971A1Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver ConditionsTOSK INC·Filed 2022·Application pending·0 cites
- 1361US12508265B2Methods and compositions for reducing radiation induced toxicityTOSK INC·Filed 2021·Granted Dec 30, 2025·0 cites·19 claims
- 1459US6365129B1Invivo high throughput toxicology screening methodTOSK INC·Filed 1999·Granted Apr 2, 2002·20 cites·16 claims
- 1559US2008189798A1Non-mammalian transgenic animal model for cellular proliferative diseasesTOSK INC·Filed 2007·Application pending·0 cites
- 1658US6316690B1Non-mammalian transgenic animal model for cellular proliferative diseasesTOSK INC·Filed 1999·Granted Nov 13, 2001·13 cites·10 claims
- 1758US2020390074A1Non-Mammalian RAS Transgenic Animal ModelTOSK INC·Filed 2020·Application pending·0 cites
- 1857US12180220B2Heteroaryl modulators of RAS GTPaseTOSK INC·Filed 2021·Granted Dec 31, 2024·0 cites·13 claims
- 1957US2022112178A1Small Molecule Modulators of RAS GTPaseTOSK INC·Filed 2021·Application pending·0 cites
- 2056US2004043486A1Methods and compositions for use in homologous recombinationTOSK INC·Filed 2003·Application pending·0 cites
- 2156US2025222000A1Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary DiseaseTOSK INC·Filed 2025·Application pending·0 cites
- 2254US12419893B2Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridineTOSK INC·Filed 2021·Granted Sep 23, 2025·0 cites·10 claims
- 2354US10660318B2Non-mammalian RAS transgenic animal modelTOSK INC·Filed 2014·Granted May 26, 2020·0 cites·10 claims
- 2450US12528796B2Modulators of RAS GTPaseTOSK INC·Filed 2020·Granted Jan 20, 2026·0 cites·23 claims
- 2548US9468613B2Doxorubicin adjuvants to reduce toxicity and methods for using the sameTOSK INC·Filed 2015·Granted Oct 18, 2016·0 cites·14 claims
- 2645US11390626B2Pyrazolopyrimidine modulators of RAS GTPaseTOSK INC·Filed 2020·Granted Jul 19, 2022·0 cites·16 claims
- 2742US2003203487A1Methods and compositions for use in homologous recombinationTOSK INC·Filed 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when TOSK INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →